20. Okt. 2018Univ.-Prof. Dr. Thomas Brodowicz

ESMO 2018: Effektive Sarkomtherapie durch aktivierte Nanopartikel

Univ.-Prof. Dr. Thomas Brodowicz, Universitätsklinik für Innere Medizin, Wien, kommentiert fünf neue Sarkomstudien, darunter zu Cabozantinib und Nanopartikel, die mittels Radiotherapie aktiviert werden.


1601O – Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017. Jean-Yves Blay (Lyon, FR)

1602O – Outcome following unplanned excision in soft tissue sarcoma. Results of a multicentre study including 728 patients. Maria A. Smolle (Graz, AT)

LBA66 – A phase II/III trial of hafnium oxide nanoparticles activated by radiotherapy in the treatment of locally advanced soft tissue sarcoma of the extremity and trunk wall. Sylvie Bonvalot (Paris, FR)

1603O – Initial Results of Phase 1 Study of DCC-2618, a Broad-spectrum KIT and PDGFRa Inhibitor, in Patients (pts) with Gastrointestinal Stromal Tumor (GIST) by Number of Prior Regimens. Suzanne George (Boston, US)

LBA67 – Cabozantinib in Patients With Advanced Osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study. Antoine Italiano (Bordeaux, FR)